Palabras clave
nefritis lúpica
inmunosupresión
inmunosupresión
Cómo citar
1.
Camargo JA, Pulido JA, Vargas JG, Achiardi RD, Echeverri JE. Desenlaces clínicos en nefritis lúpica. Reporte de una serie de casos del Hospital Militar Central de Bogotá. Rev. Colomb. Nefrol. [Internet]. 1 de julio de 2014 [citado 3 de julio de 2024];1(2):98-103. Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/181
Resumen
La presente serie retrospectiva de casos, pretende describir las características y desenlaces clínicos de los pacientes del Hospital Militar Central de Bogotá, con nefritis lúpica proliferativa. Es frecuente encontrar al momento del diagnóstico proteinuria, 37% de ellas en rango nefrótico y alteraciones en el uroanálisis.
Describimos los resultados de las principales variables hematológicas e inmunológicas. No encontramos diferencias entre los tipos de inducción ni en los desenlaces como: porcentaje de remisión, disminución de creatinina y reducción de proteinuria.
Citas
1. Kdigo Clinical Practice Guideline For glomerulonephritis. Chapter 12: Lupus nephritis. Kidney International Supplements
2012;2:221–232.
2. Gourley M, Austin H, Scott D, et al. Metthylprednisolone and Cyclophosphamide, alone or in combination in patients
with Lupus Nephritis. Ann InternMed 1996;125:549-557.
3. Hossiau FA, Vasconcelos C, DCruz D, et al. Immuno suppressive therapy in lupus nephritis: The Eurolupus. Arthritis Rheum 2002;46:2121-2131.
4. Isenberg D, Appel G, Contreras. Et al. Influence of race/ethnicity on response to lupus nephritis treatment. Rheumatology 2010;49:128–140.
5. Anaya J, Cañas C, Mantilla R. Lupus nephritis in Colombians, contrasts an comparison with other population. Clinical
Reviews in Allergy & Immunology 2011;40:199–207.
6. Ramsey-Goldman R, Isenberg D. Systemic Lupus Erythematosus Measures Arthritis & Rheumatism 2003; 49 (5S): S225–S233.
7. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005;14:39–44.
8. Pinto Peñaranda LF, Castro Mercado IL, Duque Caballero V, et al. Predictive risk factors for failure to induction therapy of lupus nephritis in a cohort of Colombian patients. ReumatolClin. 2014;10(3):147-51.
9. Clark W, Sontrop J. What have we learned about optimal induction therapy for lupus nephitis (III through V) form
Randomized controlled trials? Clin J Am SocNephrol 2008;3:895-898.
10. Bertsias G, Ioannidis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008:67;195–205.
11. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15(2):94-101.
12. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14(11):890-5.
13. Chan T, Eung F, et al. Efficacy of mycophenolatemofetil in patients with diffuse proliferative lupus nephritis. N Eng J Med 2000;343:1156-62.
14. Chan T, Tse K. Long term study of mycophenatemofetil as continuous induction and maintenance treatment for diffuse
proliferative lupus nephritis. J Am SocNephrol 2005;16:1076-1084.
15. Ginzler E, Dooley M, et al. MycophenolateMofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N Engl J Med 2005;353:2219-28.
16. Contreras G, Pardo V, et al. Sequential Therapies for Proliferative Lupus Nephritis. N Engl J Med 2004;350:971-80.
17. Sinclair A, Appel G, et al. Mycophenolatemofetil as induction and maintenance therapy for lupus nephritis: rationale
and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972–980.
18. ONG L, HOOI L, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolatemofetil in the induction therapy of proliferative lupus nephritis. Nephrol 2005;10:504–510.
19. Walsh M, James M, et al. MycophenolateMofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta- nalysis. Clin J Am SocNephrol 2007;2:968-975.
20. Zhu B, Chen N. Mycophenolatemofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007;22:1933–1942
2012;2:221–232.
2. Gourley M, Austin H, Scott D, et al. Metthylprednisolone and Cyclophosphamide, alone or in combination in patients
with Lupus Nephritis. Ann InternMed 1996;125:549-557.
3. Hossiau FA, Vasconcelos C, DCruz D, et al. Immuno suppressive therapy in lupus nephritis: The Eurolupus. Arthritis Rheum 2002;46:2121-2131.
4. Isenberg D, Appel G, Contreras. Et al. Influence of race/ethnicity on response to lupus nephritis treatment. Rheumatology 2010;49:128–140.
5. Anaya J, Cañas C, Mantilla R. Lupus nephritis in Colombians, contrasts an comparison with other population. Clinical
Reviews in Allergy & Immunology 2011;40:199–207.
6. Ramsey-Goldman R, Isenberg D. Systemic Lupus Erythematosus Measures Arthritis & Rheumatism 2003; 49 (5S): S225–S233.
7. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005;14:39–44.
8. Pinto Peñaranda LF, Castro Mercado IL, Duque Caballero V, et al. Predictive risk factors for failure to induction therapy of lupus nephritis in a cohort of Colombian patients. ReumatolClin. 2014;10(3):147-51.
9. Clark W, Sontrop J. What have we learned about optimal induction therapy for lupus nephitis (III through V) form
Randomized controlled trials? Clin J Am SocNephrol 2008;3:895-898.
10. Bertsias G, Ioannidis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008:67;195–205.
11. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006;15(2):94-101.
12. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14(11):890-5.
13. Chan T, Eung F, et al. Efficacy of mycophenolatemofetil in patients with diffuse proliferative lupus nephritis. N Eng J Med 2000;343:1156-62.
14. Chan T, Tse K. Long term study of mycophenatemofetil as continuous induction and maintenance treatment for diffuse
proliferative lupus nephritis. J Am SocNephrol 2005;16:1076-1084.
15. Ginzler E, Dooley M, et al. MycophenolateMofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N Engl J Med 2005;353:2219-28.
16. Contreras G, Pardo V, et al. Sequential Therapies for Proliferative Lupus Nephritis. N Engl J Med 2004;350:971-80.
17. Sinclair A, Appel G, et al. Mycophenolatemofetil as induction and maintenance therapy for lupus nephritis: rationale
and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007;16:972–980.
18. ONG L, HOOI L, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolatemofetil in the induction therapy of proliferative lupus nephritis. Nephrol 2005;10:504–510.
19. Walsh M, James M, et al. MycophenolateMofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta- nalysis. Clin J Am SocNephrol 2007;2:968-975.
20. Zhu B, Chen N. Mycophenolatemofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007;22:1933–1942
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de Creative Commons Reconocimiento- NoComercial- SinObraDerivada 4.0 Internacional. que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.